Quince Therapeutics, Inc.

Ownership Transactions Reported by 21 Insiders

Symbol
QNCX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
611 Gateway Blvd., Suite 273, South San Francisco, CA

There are no Buy or Sell transactions made by insiders since 11/25/2024

Quince Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Stephen S. Dominy Chief Scientific Officer, Director $1.35M Jan 3, 2022
Dirk Thye CEO and CMO, Director $1.21M Jun 18, 2025
Casey Lynch Chief Executive Officer, Director $1.11M Jan 3, 2022
Philip S. Low Director $488K May 19, 2022
Brendan Hannah Cbo, Coo & Cco $406K Jun 18, 2025
Christopher P. Lowe Interim CEO, COO & CFO $249K Mar 3, 2022
Karen L. Smith Chief Medical Officer $183K Feb 1, 2023
Charles S. Ryan President $157K Jun 18, 2025
Leslie Holsinger EVP, Preclinical Development $139K Jun 6, 2022
Michael J. Detke Chief Medical Officer $132K Mar 3, 2022
Caryn Gordon McDowell Chief Legal & Adm. Officer $115K Jun 6, 2022
Ted Monohon Chief Accounting Officer & VP $25.8K Mar 6, 2023
Guenter Janhofer Chief Scientific Officer $14.1K Oct 23, 2023
Marwan Sabbagh Director Mar 14, 2022
Margaret McLoughlin Director Jun 4, 2025
Christopher J. Senner Director Jun 4, 2025
David Lamond Director Jun 4, 2025
June Bray Director Jun 4, 2025
Rajiv Patni Director Jun 4, 2025
Una S. Ryan Director Jun 4, 2025
Benatti Luca Director Jun 4, 2025

Recent Insider Transactions by Companies or Individuals for Quince Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.